Vallon Pharmaceuticals, Inc. (VLON) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Philadelphia, PA, アメリカ. 現CEOは David C. Baker.
VLON を有する IPO日 2021-02-10, 2 名の正社員, に上場 NASDAQ Capital Marke.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
